Clinical Trials Logo

Clinical Trial Summary

Observational, Multicenter, Post-market, Minimal risk, Prospective data collection of PillCam SB3 videos (including PillCam reports) and raw data files and optional collection of Eneteroscopy reports


Clinical Trial Description

Up to 8000 PillCam SB3 videos (including PillCam reports) and raw data files will be collected in up to 50 medical centers in the US. Study duration is up to 7 years from IRB approval. Medical center study sites will provide relevant videos (including PillCam reports) and raw data from patients who underwent SB3 procedures. Per patient demographic data will be also collected to provide a description of the study population characteristics and disposition. Additional Standard of care data collection might be performed (optional). This data will include a de-identified Eneteroscopy report, from patients enrolled to the study and referred to Eneteroscopy procedure (all types of Eneteroscopies), following findings identified during the PillCamTM SB procedure, as part of the standard of care procedure. This data might be collected retrospectively for enrolled patients who underwent an Eneteroscopy procedure. The de-identified reports will be used by MDT GI research and development team to further develop and validated SB capsule localization. Study subjects will not undergo any additional procedures, nor will their diagnosis and subsequent treatment pathway be changed for the purpose of the registry. The data will be used by MDT GIs research and development team for the development and validation of improved and new detectors in the PillCam software. The videos (including PillCam reports) and raw data files will be de-identified at the medical center by representatives who are authorized and delegated to review medical records, prior to providing them to the sponsor. All data in the study- videos, reports, raw data files and demographic information will be de-identified in a manner that is untraceable by the sponsor clinical study team members. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03771508
Study type Observational
Source Medtronic - MITG
Contact Gemachu Rabu
Phone 1.774.245.8756
Email gemachu.rabu@medtronic.com
Status Recruiting
Phase
Start date December 13, 2018
Completion date December 30, 2025

See also
  Status Clinical Trial Phase
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Completed NCT00897923 - Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma N/A
Completed NCT00003993 - Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma Phase 1
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT00956475 - Quality of Life in Younger Leukemia and Lymphoma Survivors Phase 1
Completed NCT00646139 - KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment Phase 1
Active, not recruiting NCT00410462 - Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Phase 2
Completed NCT00562380 - AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma Phase 1
Completed NCT00049400 - S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction Phase 1
Completed NCT00049699 - VNP40101M in Treating Patients With Advanced or Metastatic Cancer Phase 1
Completed NCT00049712 - Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma Phase 1
Completed NCT00006348 - Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Phase 3
Completed NCT00004904 - Stem Cell Transplantation in Treating Patients With Hematologic Cancer Phase 1
Completed NCT00004895 - Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Phase 2
Completed NCT00005804 - Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Phase 2
Completed NCT00004189 - Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer Phase 1
Completed NCT00019019 - Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Phase 1
Withdrawn NCT00621036 - Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Phase 2
Completed NCT00987766 - Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Phase 1